Affinity crosslinking of I-labeled human ß-endorphin to cell lines possessing either μ- or δ-type opioid binding sites

The specific labeling of opioid receptor-related polypeptides was compared in two cell lines which differ in their opioid receptor population: SK-N-SH which contains predominantly μ-type opioid receptors, and NG-108-15, which contains exclusively δ-type opioid receptors. Labeling of opioid receptors was achieved by affinity cross-linking of membranes, using ¹²⁵I-labeled human ß-endorphin, followed by solubilization in sodium dodecyl sulphate (SDS), SDS-gel electrophoresis and autoradiography. Different labeling patterns were obtained from these two cell lines. In SK-N-SH cells, 3 major proteins were labeled, corresponding to molecular weights of 92, 65 and 25 kDa, while in the NG-108-15 cells, 53-kDa and 25-kDa polypeptides were the major ones labeled. The radioactivity incorporated into the 92- and 65-kDa peptide bands derived from SK-N-SH cells was displayed by the μ-selective ligand Tyr- -Ala-Gly-MePhe-Gly-ol (DAGO) but not by the δ-selective ligand [ -Pen², -Pen⁵]enkephalin (DPDPE). The radioactivity incorporated into the NG-108-15-derived peptide bands was displaced by the δ-selective ligand, but not by the μ-selective ligand. This confirms our previous finding in mammalian brain which demonstrated that μ- and δ-opioid binding sites can be identified as distinct proteins which differe in molecular size.     

Comparison of G-protein activation in the brain by μ-, δ-, and κ-opioid receptor agonists in μ-opioid receptor knockout mice

Mice lacking the μ-opioid receptor gene have been developed by a gene knockout procedure. In this study, the activity of opioid receptor coupled G-proteins was examined to investigate whether there is a change in the extent of coupling for μ-, δ-, and κ-opioid receptors in μ-opioid receptor knockout mice. Selective agonists of μ- (DAMGO), δ- (DPDPE), and κ- (U-69,593) opioid receptors stimulated [³⁵S]GTPγS binding in the caudate putamen and cortex of wild-type mice. In contrast, only U-69,593 stimulated [³⁵S]GTPγS binding in these regions of μ-opioid receptor knockout mice. These results confirmed the absence of G-protein activation by a μ-opioid receptor agonist in μ-opioid receptor knockout mice, and demonstrated that coupling of the κ-opioid receptor to G-proteins is preserved in these mice. However, G-protein activation by the δ-opioid receptor agonist, DPDPE, was reduced in the μ-opioid receptor knockout mice, at least in the brain regions studied using autoradiography.     

Enkephalins modulate excitatory synaptic transmission in the superficial dorsal horn by acting at μ-opioid receptor sites

The effect of opioids on synaptic potentials of dorsal horn (DH) neurons has been investigated in a rat spinal cord DH slice-dorsal root ganglion (DRG) in vitro preparation. Conventional intracellular recording from DH and DRG neurons using 3 M potassium acetate-filled electrodes was employed. Dorsal roots were electrically isolated from the spinal cord slice and stimulated with pulses of different intensity and duration to evoke afferent action potentials monitored intracellularly from DRG neurons. Low-intensity single-shock stimulation of the dorsal roots (8–20 V pulses of 0.02–0.05 ms duration) activated large primary afferents and elicited excitatory postsynaptic potentials (EPSP) in all of the neurons tested. High-intensity stimulation of the dorsal roots (over 35 V pulses of 0.5 ms duration), sufficient to excite small myelinated and unmyelinated primary afferents resulted in a large and prolonged depolarization of DH neurons associated with firing of action potentials. Bath application (d-Ala², N-Me-Phe⁴,Gly⁵-ol)-enkephalin (DAGO), (d-Ala², d-Leu⁵)-enkephalinamide (DADLEA), or (d-Ala², d-Met⁵)-enkephalinamide (DADMEA) produced dose-dependent, reversible hyperpolarization in about 75% of the neurons tested. The hyperpolarization was associated with a fall in neuronal input resistance. In addition, opioids depressed the synaptic transmission in all of the neurons examined. This depressant effect of opioids was independent from their effects on resting membrane potential. Delta specific receptor opioid agonists (d-Pen^2.5)-enkephalin (DPDPE) and (d-Pen², l-Pen⁵)-enkephalin (DPLPE), were completely ineffective in producing an effect on neuronal membrane or synaptic transmission. All opioid effects were antagonized by naloxone.     

Opioid receptor affinities of kappa agonists, agonist/antagonists and antagonists in vitro and in vivo

1. 1. The CMS opioid receptors consist of a major triad: μ, δ and κ.

2. 2. The κ agonists presently available act as κ agonists, δ antagonists and μ₂ isoreceptor antagonists.

3. 3. Pure opiate antagonists possess a broad spectrum of activity at all 3 opioid receptor populations.

4. 4. The Ag/Ant analgesics also possess a broad spectrum of receptor affinities which awaits the definition of complex species differences in their actions.

5. 5. The design of more specific opioid agonists and antagonists will lead to a greater understanding of the many possible roles opioids serve within the CNS.

Characterization of mechanical withdrawal responses and effects of μ-, δ- and κ-opioid agonists in normal and μ-opioid receptor knockout mice

Clinical and experimental observations suggest that opiates can exert different influences on the perception of stimuli from distinct sensory modalities. Thermally-induced nociception is classically responsive to opiate agonists. μ-Opioid receptor-deficient transgenic mice are more sensitive to thermal nociceptive stimuli and morphine fails to attenuate the nociceptive responses to thermal stimuli in these animals. To enhance our understanding of opiate influences on mechanical sensitivity, we have examined withdrawal responses to a sequence of ascending forces of mechanical stimuli in mice with normal (wild type), half-normal (heterozygous) and absent (homozygous) μ-opioid receptor levels. We report data from mice examined without drug pretreatment or following pretreatment with morphine, the selective κ-opioid agonist, U50488H, and the selective δ-opioid agonist, DPDPE. Saline-pretreated mice of each genotype displayed similar, monotonically increasing frequency of withdrawal responses to the graded stimuli. Subcutaneously administered morphine produced a dose-dependent reduction in withdrawal responses in wild type and heterozygous mice, but had no significant effect in homozygous mice. Intraventricular administration of DPDPE also reduced the frequency of paw withdrawal (FPW) in wild type mice, but not in homozygous mice. In contrast, systemic U50488H produced a dose-dependent attenuation of paw withdrawal in both wild type and homozygous mice. These findings suggest that (1) interactions of endogenous peptides with μ-opioid receptors may not play a significant role in the response to mechanical stimuli in drug-free animals, and (2) deficiency of μ-opioid receptors has no functional consequence on the response to the prototypical κ-opioid receptor agonist, but decreases responses to the prototypical μ- and δ-opioid receptor agonists.     

Ventral pallidal microinjections of receptor-selective opioid agonists produce differential effects on circling and locomotor activity in rats

Locomotor activity was investigated following microinjections of receptor-selective opioid agonists into the ventral pallidum (VP) of rats. In Expt. 1, male Long-Evans rats were treated with unilateral microinjections of the μ agonist [d-Ala²-MePhe⁴, Gly-ol⁵]-enkephalin (DAGO), the σ agonist [d-Pen²,d-Pen⁵]-enkephalin (DPDPE) or the κ agonist U50,488H, and the rate and duration of circling behavior were measured. DAGO (0.01, 0.1, 1.0 nmol) procedure a dose-dependent increse in contralateral circling; pretreatment with 1.0 mg/kg naltrexone blocked the circling induced by the highest dose. The behavioral effect was largest when injections were targeted at the VP rather than structures dorsal to the VP. In contrast to DAGO, intrapallidal DPDPE (0.01, 0.1, 1.0, 10.0 nmol) produced a slight increase in contralateral circling only at the highest dose and U50, 488H (0.01, 0.1, 1.0, 10.0 nmol) produced no effect. In Expt. 2, the effects of bilateral injections of DAGO, DPDPE and U50,488H were tested in photocell activity ☐es. DAGO produced a dose-dependent increase in locomotor activity and this increase was decreased by 1.0 mg/kg naltrexone. A slight increase in activity was observed with the highest dose of DPDPE, and a slight decrease was observed with the highest dose of U50,488H. These findings confirm that opiate actions in the VP contribute to opiate-induced locomotion and suggest that μ and to some extent σ receptors are involved in this behavior.     

Pharmacological characterization of the ameliorating effect on short-term memory impairment and antinociceptive effect of KT-90 in mice

(−)-3-Acetyl-6β-acetylthio-N-cyclopropylmethyl-normorphine (KT-90) is a synthesized compound that binds to μ-, δ- and κ-opioid receptors in vitro. KT-90 induces analgesia in the tail-flick test and this effect is antagonized by nor-BNI, a selective κ-opioid receptor antagonist. However, lower doses of KT-90 antagonize morphine-induced analgesia. We reported that κ-opioid receptor agonists such as U-50,488H and dynorphin A (1-13), improved scopolamine-induced impairment of learning and memory in mice and/or rats. In this study, the effects of KT-90 were investigated in an acetic acid-induced writhing test and scopolamine-induced memory impairment test using spontaneous alternation performance in a Y-maze. Male ddY mice were treated with scopolamine (1.65 μmol/kg, s.c.) 30 min before the behavioral test. KT-90 (0.07–2.35 μmol/kg, s.c.) was injected 30 min before testing. In the writhing test, the antinociceptive effect of KT-90 (0.71 μmol/kg) was completely antagonized by a selective μ-opioid receptor antagonist, β-funaltrexamine (10.2 nmol/mouse, i.c.v.) and partially antagonized by nor-BNI (4.9 nmol/mouse, i.c.v.), but it was not antagonized by a selective δ-opioid receptor antagonist, naltrindole (9.1 pmol/mouse, i.c.v.). KT-90 significantly improved the impairment of spontaneous alternation induced by scopolamine. The ameliorating effect of KT-90 was not antagonized by nor-BNI, but was almost completely antagonized by a selective σ receptor antagonist, NE-100 (2.6 μmol/kg, i.p.). These results suggested that the KT-90-induced antinociceptive effect was mediated by μ- and partially by κ-opioid receptors, and the KT-90-induced improvement in scopolamine-induced impairment of spontaneous alternation was mediated mainly via σ receptors.     

General, μ and κ opioid antagonists in the nucleus accumbens alter food intake under deprivation, glucoprivic and palatable conditions

Ventricular microinjection studies found that whereas μ (β-funaltrexamine, B-FNA), μ₁ (naloxonazine) and κ (nor-binaltorphamine, Nor-BNI) opioid receptor antagonists, but not δ antagonists, reduce deprivation-induced intake, κ and μ, but not μ₁ or δ antagonists reduce both 2-deoxy- d-glucose (2DG) hyperphagia and sucrose intake. Since opioid agonists stimulate spontaneous food intake in the accumbens, the present study examined whether administration of either naltrexone, B-FNA or Nor-BNI in the accumbens altered intake under deprivation (24 h), glucoprivic (2DG: 500 mg/kg, i.p.) or palatable sucrose (10%) conditions. Naloxonazine's effects in the accumbens were also evaluated for deprivation-induced intake. Deprivation-induced intake was significantly decreased over 4 h by naltrexone (5–20 μg, 44%), B-FNA (1–4 μg, 55%) and Nor-BNI (4 μg, 31%), but not naloxonazine (10 μg) in the accumbens. 2DG hyperphagia was significantly decreased by naltrexone (10–20 μg, 79%), B-FNA (1–4 μg, 100%) and Nor-BNI (1–4 μg, 75%) in the accumbens. Sucrose intake was significantly decreased by naltrexone (50 μg, 27%) and B-FNA (1–4 μg, 37%), but not Nor-BNI in the accumbens. These data suggest that μ receptors, and particularly the μ₂ binding site in the accumbens are responsile for the opioid modulation of these forms of intake in this nucleus, and that this control may be acting upon the amount of intake per se.     

Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by μ-opioid agonists, but not by δ- and κ-opioid agonists

To investigate the possible mechanisms of the alterations in morphine-induced analgesia observed in diabetic mice, we examined the influence of streptozotocin-induced (STZ-induced) diabetes on analgesia mediated by the different opioid receptors. The antinociceptive potency of morphine (10 mg/kg), administered s.c., as determined by both the tail-pinch and the tail-flick test, was significantly reduced in diabetic mice as compared to that in controls. Mice with STZ-induced diabetes had significantly decreased sensitivity to intracerebroventricularly (i.c.v.) administered μ-opioid agonists, such as morphine (10 μg) and [d-Ala², N-Me Phe⁴,Gly-ol⁵]enkephalin (DAMGO, 0.5 μg). However, i.c.v. administration of [d-Pen^2,5]enkephalin (DPDPE, 5 μg), a δ-opioid agonist, and U-50,488H (50 μg), a κ-opioid agonist, produced pronounced antinociception in both control and diabetic mice. Furthermore, there were no significant differences in antinociceptive potency between diabetic and control mice when morphine (1 μg), DAMGO (10 μg), DPDPE (0.5 μg) or U-50,488H (50 μg) was administered intrathecally. In conclusion, mice with STZ-induced diabetes are selectively hyporesponsive to supraspinal μ-opioid receptor-mediated antinociception, but they are normally responsive to activation of δ- and κ-opioid receptors.     

Dissociation of μ and δ opioid receptor-mediated reductions in evoked and spontaneous synaptic inhibition in the rat hippocampus in vitro

Modulation of γ-aminobutyric acid (GABA)-mediated inhibition, and glutamate-mediated excitation by highly selective μ and δ opioid agonists was studied using intracellular recordings of CA1 pyramidal neuron synaptic responses in superfused hippocampal slices. Equimolar concentrations of the selective μ agonist,

Full-size image

(DAGO), or the δ selective agonist, [ -Pen², -Pen⁵]-enkephalin (DPDPE), reversibly increased the amplitudes of excitatory post-synaptic potentials (EPSPs), evoked by Schaffer collateral/commissural stimulation, without altering the input resistance or resting membrane potential of these CA1 pyramidal neurons. The increased EPSP amplitudes resulting from superfusion with the enkephalin analogs were qualitatively similar to those caused by the GABA_A receptor antagonist, bicuculline methiodide (BM1). Specific stimulation/recording protocols and micro-lesions of the slices were used to evoke relatively pure forms of recurrent and feed-forward GABA-mediated inhibitory post-synaptic potentials (IPSPs). The μ opioid agonist DAGO reduced both recurrent and feed-forward IPSPs, while the δ agonist DPDPE had no effect upon these responses. To test the hypothesis that the enhancement of pyramidal neuron EPSPs by δ (and μ) opioids was due to the reduction of an inhibitory potential that was coincident with the EPSP, DPDPE or the μ agonist, DAGO, were applied while recording monosynaptic IPSPs following the elimination of EPSPs by the glutamate receptor antagonists, -2-amino-5-phosphonovalerate (APV) and 6,7-dinitroquinoxaline-2,3-dione (DNQX). The μ agonist, DAGO, reversibly reduced these pharmacologically isolated IPSPs, while the δ agonist, DPDPE, had no effect upon these responses. Despite the fact that the δ agonist, DPDPE, had no effect on recurrent, feed-forward or monosynaptic evoked IPSPs, this enkephalin did reversibly reduce the frequency of spontaneously occurring IPSPs, measured using whole-cell recordings with pipettes containing 65 mM KC1. The μ agonist, DAGO, and the GABA_A antagonist. BMI, similarly reduced spontaneous IPSP rates. We conclude from these data that μ and δ opioid receptor activation increases EPSPs via the reduction of a form of GABAergic inhibition that is difficult to characterize, and which may be distinct from conventional feed-forward and recurrent inhibition. Furthermore, δ opioids seem to reduce this form of GABAergic inhibition selectively, while μ opioids reduced this inhibition, and conventional feed-forward and recurrent IPSPs as well.     

Etorphine elicits anomalous excitatory opioid effects on sensory neurons treated with GM1 ganglioside or pertussis toxin in contrast to its potent inhibitory effects on naive or chronic morphine-treated cells

The ultra-potent opioid analgesic, etorphine, elicits naloxone-reversible, dose-dependent inhibitory effects, i.e. shortening of the action potential duration (APD) of naive and chronic morphine-treated sensory dorsal root ganglion (DRG) neurons, even at low (pM-nM) concentrations. In contrast, morphine and most other opioid agonists elicit excitatory effects, i.e. APD prolongation, at these low opioid concentrations, require much higher (ca. 0.1–1 μM) concentrations to shorten the APD of naive neurons, and evoke only excitatory effects on chronic morphine-treated cells even at high > 1–10 wM concentrations. In addition to the potent agonist action of etorphine at μ-, δ- and κ-inhibitory opioid receptors in vivo and on DRG neurons in culture, this opioid has also been shown to be a potentantagonist of excitatory μ-, δ- and κ-receptor functions in naive and chronic morphine-treated DRG neurons. The present study demonstrates that the potent inhibitory APD-shortening effects of etorphine still occur in DRG neurons tested in the presence of a mixture of selective antagonists that blocks all μ-, δ- and κ-opioid receptor-mediated functions, whereas addition of the epsilon (ε)-opioid-receptor antagonist, β-endorphin(1–27) prevents these effects of etorphine. Furthermore, after markedly enhancing excitatory opioid receptor functions in DRG neurons by treatment with GM1 ganglioside or pertussis toxin, etorphine showsexcitatory agonist action onnon-μ-/δ-/κ-opioid receptor functions in these sensory neurons, in contrast to its usual potent antagonist action on μ-, δ- and κ-excitatory receptor functions in naive and even in chronic morphine-treated cells which become supersensitive to the excitatory effects of μ-, δ- and -opioid agonists. This weak excitatory agonist action of etorphine on non-μ-/δ-/κ-opioid receptor functions may account for the tolerance and dependence observed after chronic treatment with extremely high doses of etorphine in vivo.     

Ionic currents in cultured supraoptic neurons: Actions of peptides and transmitters

The hypothalamo-neurohypophysial system has proved an excellent model for peptidergic neurons in the central nervous system. Electrophysiological studies using in vivo and in vitro preparations with extracellular and intracellular recording techniques have determined some of the intrinsic and extrinsic mechanisms that generate the striking firing patterns that the neurons exhibit. We have developed a dissociated cell preparation of these neurons and used patch clamp recording techniques to enable detailed studies of membrane properties underlying such activities. Cultured neonatal supraoptic neurons fired spontaneous action potentials which in some cells were distinctively patterned. Under voltage clamp, voltage-activated Na⁺, K⁺, and Ca²⁺ currents were recorded. K⁺ and Ca²⁺ currents were modulated by application of -adrenergic agonists, and Ca²⁺ currents were also modulated by κ-opioid agonists. The neurons were also sensitive to γ-aminobutyric acid which acted directly on Cl-channels. Spontaneous, patterned activity, the presence of functional receptors for neurotransmitters and the ability to study the neurons under voltage clamp suggest that this is an excellent model system for studying these peptidergic neurons.     

The cloned μ, δ and κ receptors and their endogenous ligands: Evidence for two opioid peptide recognition cores

The opioid peptides are derived from three prohormone precursors referred to as proopiomelanocortin (POMC), proenkephalin (ProEnk) and prodynorphin (ProDyn). Following specific cleavage, several biologically active peptides are generated that can bind the μ, δ and κ receptors. The present study examines the receptor binding affinities of the POMC, ProEnk and ProDyn peptides to the cloned μ, δ and κ receptors expressed transiently in transfected COS-1 cells. Consistent with previous findings using brain homogenates, competition studies demonstrate that no opioid peptide family can be exclusively associated with a specific opioid receptor type. Short ProEnk peptides, such as Leu- and Met-enkephalin are selective for δ, but C-terminally extended peptides such as Met-Enk-Arg-Gly-Leu and Met-Enk-Arg-Phe have a high affinity to μ, δ and κ. Similarly, Peptide E, the BAM peptides, and metorphamide have a high affinity for all three opioid receptors types. While dynorphin A peptides and - and β-neoendorphin have a preference for κ, they also bind the cloned δ and μ receptors. Our findings do not easily fit a simple ‘message-address’ model where the Try-Gly-Gly-Phe core is extended and this gradually alters selectivity. Rather, the pattern appears more discontinuous, and would fit better with the idea of two similar but distinct cores; a Tyr-Gly-Gly-Phe Met- or Leu core that is necessary and sufficient for μ and δ but not κ and a Tyr-Gly-Gly-Phe-Met or Leu core with an Arg-X extension that is equally necessary and sufficient for κ.     

Neostriatal dopaminergic terminals prevent the GABAergic involvement in the μ- and δ-opioid inhibition of KCl-evoked endogenous acetylcholine release

Endogenous acetylcholine (ACh) release from rat neostriatal slices were inhibited by the μ-opioid agonist [d-Ala²,Gly(ol)⁵]-enkephalin (DAGO) both in 6-hydroxydopamine (6-OHDA)-lesioned and non-lesioned neostriatum. However, the δ-opioid agonist [d-Pen², d-Pen⁵]-enkephalin (DPDPE) could not inhibit KCl-evoked ACh release in the 6-OHDA-lesioned striatum. This results suggests that δ-opioid agonist act on dopaminergic terminals to inhibit the cholinergic neurons. In unlesioned rats, GABA_A or GABA_B antagonists (bicuculline or phaclofen, respectively) prevented μ- or δ-opioid inhibition of endogenous ACh release evoked by glutamate, but not by potassium. However, in the 6-OHDA-lesioned side, DAGO inhibition of KCl-evoked ACh release was antagonized by either of the GABA antagonists. Our results suggest that the dopaminergic neurotransmission, favored by KCl, blocks the GABAergic involvement in the μ- and δ-opioid inhibition of endogenous ACh release.     

δ-, but not μ- and κ-, opioid receptor activation protects neocortical neurons from glutamate-induced excitotoxic injury

Recent observations from our laboratory have led us to hypothesize that δ-opioid receptors may play a role in neuronal protection against hypoxic/ischemic or glutamate excitotocity. To test our hypothesis in this work, we used two independent methods, i.e., “same field quantification” of morphologic criteria and a biochemical assay of lactate dehydrogenase (LDH) release (an index of cellular injury). We used neuronal cultures from rat neocortex and studied whether (1) glutamate induces neuronal injury as a function of age and (2) activation of opioid receptors (δ, μ and κ subtypes) protects neurons from glutamate-induced injury. Our results show that glutamate induced neuronal injury and cell death and this was dependent on glutamate concentration, exposure period and days in culture. At 4 days, glutamate (up to 10 mM, 4 h-exposure) did not cause apparent injury. After 8–10 days in culture, neurons exposed to a much lower dose of glutamate (100 μM, 4 h) showed substantial neuronal injury as assessed by morphologic criteria (>65%, n=23, P<0.01) and LDH release (n=16, P<0.001). Activation of δ-opioid receptors with 10 μM DADLE reduced glutamate-induced injury by almost half as assessed by the same criteria (morphologic criteria, n=21, P<0.01; LDH release, n=16, P<0.01). Naltrindole (10 μM), a δ-opioid receptor antagonist, completely blocked the DADLE protective effect. Administration of μ- and κ-opioid receptor agonists (DAMGO and U50488H respectively, 5–10 μM) did not induce appreciable neuroprotection. Also, μ- or κ-opioid receptor antagonists had no appreciable effect on the glutamate-induced injury. This study demonstrates that activation of neuronal δ-opioid receptors, but not μ- and κ-opioid receptors, protect neocortical neurons from glutamate excitotoxicity.     

Antinociception produced by receptor selective opioids. Modulation of supraspinal antinociceptive effects by spinal opioids

This study evaluated the antinociceptive effects produced when different combinations of supraspinal μ- and δ-opioid agonist were co-administered with spinal μ-, δ-, and κ-opioid agonist. Using the Randall-Selitto paw-withdrawal test, in the rat, changes in nociceptive thresholds were measured following co-administration of sequentially increasing i.c.b. doses of either DAMGO or DPDPE with a low-antinociceptive dose of intrathecal DAMGO, DPDPE, or U50,488H. Antinociceptive synergy (i.e. a more than additive antinociceptive effect) was demonstrated with all of the combinations tested except for supraspinal DPDPE co-administered with spinal DAMGO. The results of this study provide support for the suggestion that supraspinal and spinal antinociceptive mechanisms share, in part, common neural circuits. Marked differences in the overall magnitude of the antinociceptive effects produced by the various combinations of opioid agonists were demonstrated through a secondary analysis of the data. When sequentially increasing i.c.v. doses of DAMGO were administered, significantly larger increases in nociceptive thresholds were observed with co-administration of intrathecal injections of low antinociceptive doses of either DAMGO or U50,488H compared to DPDPE. In contrast, when DPDPE was administered supraspinally, the largest increases in nociceptive thresholds were demonstrated with co-administration of DPDPE at the spinal site. The results of the secondary analysis provide support for the hypothesis that descending antinociceptive control systems activated by supraspinal administration of selective μ- and δ-opioid agonists interact, differently, with spinal μ-, δ, and κ-opioidergic mechanisms.     

Pharmacological and anatomical evidence of selective μ, δ, and χ opioid receptor binding in rat brain

While the distribution of opioid receptors can be differentiated in the rat central nervous system, their precise localization has remained controversial, due, in part, to the previous lack of selective ligands and insensitive assaying conditions. The present study analyzed this issue further by examining the receptor selectivity of [³H]DAGO (Tyr-d-Ala-Gly-MePhe-Gly-ol), [³H]DPDPE (2-d-penicillamine-5-d-penicillamine-enkephalin), [³H]DSLET (Tyr-d-Ser-Gly-Phe-Leu-Thr) and [³H](−)bremazocine, and their suitability in autoradiographically labelling selective subpopulations of opoiod receprtors in rat brain. The results from saturation, competitions, and autoradiographic experiments indicated that the three opioid receptor subtypes can be differentiated in the rat brain and that [³H]-DAGO and [³H]DPDPE selectively labelled μ and δ binding sites, respectively. In contrast, [³H]DSLET was found to be relatively non-selective, and labelled both μ and δ sites. [³H]Bremazocine was similarly non-selective in the absence of μ and δ ligands and labelled all three opioid receptor subtypes. However, in the presence of 100 nM DAGO and DPDPE, concentrations sufficient to saturate the μ and δ sites, [³H]bremazocine did label χ sites selectively. The affinity [³H]bremazocine binding sites showed a unique distribution with relatively dense χ labelling in the hypothalamus and median eminence, areas with extremely low μ and δ binding. These results point to the selectivity, under appropriate conditions, of [³H]DAGO, [³H]DPDPE and [³H]bremazocine and provide evidence for the differential distribution of μ, δ, and χ opioid receptors in rat brain.     

Selective opioid δ agonists elicit antinociceptive supraspinal/spinal synergy in the rat

A multiplicative antinociceptive interaction of morphine activity at supraspinal and spinal sites has been clearly established and is thought to be responsible, in part, for the clinical utility of this compound in normal dose-ranges. While synergistic actions of μ-opioid receptor agonists have been shown, it is unclear whether a similar interaction exists for opioid agonists acting via δ-opioid receptors. Responses to acute nociception were determined with the 52°C hot plate, 52°C warm-water tail-flick and the Hargreaves paw-withdrawal tests. The peptidic opioid δ₁ agonist [ -Pen², -Pen⁵]enkephalin (DPDPE) or δ₂ agonist [ -Ala²,Glu⁴]deltorphin (DELT) were given into the rostral–ventral medulla (RVM), intrathecally (i.th.) or simultaneously into both the RVM and i.th. (1:1 fixed ratio). Both of the opioid δ agonists produced dose-dependent antinociception in all tests. With the exception of DPDPE in the hot plate test, isobolographic analysis revealed that the supraspinal/spinal antinociceptive interaction for both DPDPE and DELT were synergistic in all nociceptive tests. These data suggest that opioid δ agonists exert a multiplicative antinociceptive interaction between supraspinal and spinal sites to acute noxious stimuli and suggest possibility that compounds acting through δ-opioid receptors may have sufficient potency for eventual clinical application.     

Intracerebroventricular treatment with an antisense oligodeoxynucleotide to κ-opioid receptors inhibited κ-agonist-induced analgesia in rats

In vivo treatment with an antisense (AS) phosphorothioate oligodeoxynucleotide (oligo) to the rat κ-opioid receptor selectively inhibited κ-mediated analgesia in the rat cold-water tail-flick test. Intracerebroventricular (i.c.v.) AS oligo significantly inhibited the analgesic effect of i.c.v. spiradoline, but not that of μ- or δ-opioid agonists. The dose-effect curve for s.c. spiradoline was shifted to the right after AS, but not missense or sense oligo treatment. Thus, AS oligos provide another technique with which to selectively manipulate opioid receptors and further support the role of non-μ opioid receptors in mediating analgesia in rats.     

Opioid peptides modulate GABAA receptor responses in neurons of bullfrog dorsal root ganglia

Effects of enkephalin and selective opioid-receptor agonists on GABA-induced current were examined in dissociated neurons of bullfrog dorsal root ganglia (DRG) by using whole-cell patch-clamp method. Leucine-(Leu)-enkephalin and methionine-(Met)-enkephalin depressed GABA_A receptor-mediated currents. DPDPE, DAMGO and dynorphin-A (Dyn-A) also depressed the inward current produced by GABA: the order of agonist potency was DPDPE ≥ DAMGO> Dyn-A. Naloxone blocked the inhibitory effects of ekephalins and other opioid agonists on the GABA current. Naltrindole (NTI), a δ-receptor antagonist, prevented the DPDPE-induced depression of the GABA current. β-Funaltrexamine (β-FNA), a μ-receptor antagonist, reduced the DAMGO-induced depression of GABA currents. Nor-binaltorphimine (nor-BNI), a κ-receptor antagonist, reduced the effects of Dyn-A in depressing the GABA current The results suggest that enkephalin down-regulates GABA_A receptor function through mainly δ- and μ-opioid receptors in bullfrog DRG neurons.